XOMA Valuation

XOMA Royalty Corp

Add to Watchlist

Advanced Chart

32.470

-0.23(-0.703%)1D

Overview
Forecast
Valuation
Earnings

XOMA Relative Valuation

XOMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XOMA is overvalued; if below, it's undervalued.

Historical Valuation

XOMA Royalty Corp (XOMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.00 is considered Undervalued compared with the five-year average of -107.13. The fair price of XOMA Royalty Corp (XOMA) is between 141.72 to 256.54 according to relative valuation methord. Compared to the current price of 32.47 USD , XOMA Royalty Corp is Undervalued By 77.09%.

Relative Value

Fair Zone

141.72-256.54

Current Price：32.47

77.09%

Undervalued

64.30

Trailing

Forward

16.06

EV/EBITDA

XOMA Royalty Corp. (XOMA) has a current EV/EBITDA of 16.06. The 5-year average EV/EBITDA is -4.75. The thresholds are as follows: Strongly Undervalued below -520.05, Undervalued between -520.05 and -262.40, Fairly Valued between 252.89 and -262.40, Overvalued between 252.89 and 510.54, and Strongly Overvalued above 510.54. The current Forward EV/EBITDA of 16.06 falls within the Historic Trend Line -Fairly Valued range.

22.34

EV/EBIT

XOMA Royalty Corp. (XOMA) has a current EV/EBIT of 22.34. The 5-year average EV/EBIT is 60.16. The thresholds are as follows: Strongly Undervalued below -1495.47, Undervalued between -1495.47 and -717.66, Fairly Valued between 837.97 and -717.66, Overvalued between 837.97 and 1615.78, and Strongly Overvalued above 1615.78. The current Forward EV/EBIT of 22.34 falls within the Historic Trend Line -Fairly Valued range.

7.00

XOMA Royalty Corp. (XOMA) has a current PS of 7.00. The 5-year average PS is 18.81. The thresholds are as follows: Strongly Undervalued below -12.17, Undervalued between -12.17 and 3.32, Fairly Valued between 34.30 and 3.32, Overvalued between 34.30 and 49.79, and Strongly Overvalued above 49.79. The current Forward PS of 7.00 falls within the Historic Trend Line -Fairly Valued range.

18.92

P/OCF

XOMA Royalty Corp. (XOMA) has a current P/OCF of 18.92. The 5-year average P/OCF is 155.64. The thresholds are as follows: Strongly Undervalued below -887.91, Undervalued between -887.91 and -366.13, Fairly Valued between 677.41 and -366.13, Overvalued between 677.41 and 1199.18, and Strongly Overvalued above 1199.18. The current Forward P/OCF of 18.92 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

XOMA Royalty Corp. (XOMA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.35. The thresholds are as follows: Strongly Undervalued below -1.29, Undervalued between -1.29 and -0.47, Fairly Valued between 1.17 and -0.47, Overvalued between 1.17 and 1.99, and Strongly Overvalued above 1.99. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

XOMA Royalty Corp (XOMA) has a current Price-to-Book (P/B) ratio of 5.41. Compared to its 3-year average P/B ratio of 2.71 , the current P/B ratio is approximately 99.52% higher. Relative to its 5-year average P/B ratio of 3.14, the current P/B ratio is about 72.42% higher. XOMA Royalty Corp (XOMA) has a Forward Free Cash Flow (FCF) yield of approximately -0.73%. Compared to its 3-year average FCF yield of -4.05%, the current FCF yield is approximately -81.99% lower. Relative to its 5-year average FCF yield of -0.75% , the current FCF yield is about -3.21% lower.

5.41

P/B

Median3y

2.71

Median5y

3.14

-0.73

FCF Yield

Median3y

-4.05

Median5y

-0.75

Competitors Valuation Multiple

The average P/S ratio for XOMA's competitors is 121.37, providing a benchmark for relative valuation. XOMA Royalty Corp Corp (XOMA) exhibits a P/S ratio of 7.00, which is -94.23% above the industry average. Given its robust revenue growth of 18.43%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Y-mAbs Therapeutics Inc

Lexicon Pharmaceuticals Inc

Olema Pharmaceuticals Inc

Loss

374.74M

CRVS.O

Corvus Pharmaceuticals Inc

689.86

427.71M

FULC.O

Fulcrum Therapeutics Inc

Loss

-100.00%

350.51M

Performance Decomposition

Market capitalization of XOMA increased by 22.62% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -15.20 to -23.65.

The secondary factor is the Revenue Growth, contributed 18.43%to the performance.

Overall, the performance of XOMA in the past 1 year is driven by P/E Change. Which is more unsustainable.

18.43%

11.09M → 13.13M

Revenue Growth

-51.45%

144.19 → 70.01

Margin Expansion

55.64%

-15.20 → -23.65

P/E Change

22.62%